Zydus Lifesciences has completed the acquisition of the remaining 14.4% stake in Zydus MedTech France SAS, making it a wholly-owned subsidiary. This move, finalized on October 24, 2025, follows an earlier acquisition of an 85.6% stake. Zydus now holds 100% of the share capital and voting rights, solidifying its control over Zydus MedTech France.
Full Ownership of MedTech France
Zydus Lifesciences announced the completion of its acquisition of Zydus MedTech France SAS. Previously, Zydus held an 85.6% share of the company. As of October 24, 2025, Zydus has successfully acquired the remaining 14.4%, giving them total control.
Details of the Acquisition
The acquisition was completed through a mandatory tender offer and subsequent squeeze-out. With this transaction, Zydus Lifesciences now holds 100% of the share capital and voting rights of Zydus MedTech France SAS. It is now a wholly-owned subsidiary.
Source: BSE
